Exact Sciences is set to join Abbott in one of the largest healthcare acquisitions in recent years. Abbott announced Thursday that it will acquire the cancer diagnostics leader in a deal valued between $21 billion and $23 billion, depending on performance milestones.
The agreement values Exact Sciences at $105 per share, strengthening Abbott’s push into the fast-growing cancer testing market. The acquisition brings Exact Sciences’ high-profile products—including Cologuard, Oncotype DX, and its multi-cancer early detection (MCED) pipeline—firmly under Abbott’s diagnostics umbrella.
Exact Sciences has become a major force in early cancer detection, precision oncology, and genetic testing. Its tests help detect cancer earlier, guide personalized treatment plans, and monitor for recurrence, making the company one of the most influential players in the industry.
Abbott CEO Robert B. Ford praised the company’s innovations, calling Exact Sciences’ brand and execution “unrivaled in the cancer diagnostics space.” He said the acquisition aligns with Abbott’s long-standing mission to tackle major global health challenges.
The deal is expected to close in Q2 of 2026, pending shareholder approval. Both companies’ boards have unanimously approved the transaction. Once completed, Exact Sciences will operate as a subsidiary of Abbott, which will see its diagnostics division exceed $12 billion in annual revenue.
Exact Sciences is projected to generate more than $3 billion in revenue this year, with high-teens organic growth—making it one of the fastest-expanding diagnostics firms in the U.S. The company will continue to operate from its Madison, Wisconsin headquarters. Chairman and CEO Kevin Conroy will stay on in an advisory role to support the transition.
Conroy said joining Abbott will accelerate the company’s mission: “Together, we can reach more patients, advance earlier detection, and deliver answers that change lives.”
As the global demand for early cancer detection continues to rise, Abbott’s acquisition of Exact Sciences positions it at the forefront of one of the most critical and competitive sectors in modern healthcare.